{"entity":{"id":"nct06465914","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","aka":[],"tldr":"A phase 3 trial of HPV quadrivalent vaccine in penile cancer, run by Shanghai Bovax Biotechnology Co., Ltd., active and no longer recruiting.","summary":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males is a phase 3 interventional study registered as NCT06465914 by Shanghai Bovax Biotechnology Co., Ltd., with 9000 participants enrolled, started 2024-07-11 and due to reach its primary completion in 2027-07-30. Interventions recorded: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo. Conditions listed: Genital Wart, Penile Cancer, Anal Cancer, PIN-1. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06465914","url":"https://clinicaltrials.gov/study/NCT06465914"}],"tags":["ctgov-ingest"],"related":[],"cancers":["penile"],"sections":[],"technologies":[],"targets":[],"drugs":["hpv-quadrivalent-vaccine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06465914","phase":"3","setting":"A Randomized, Double-blinded, Multicenter and Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Recombinant Vaccine (Hansenula Polymorpha) in Chinese Males Aged 18-45 Years","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","enrolled":9000,"outcomes":[]},"route":"/trials/nct06465914/","neighbours":{"cancer":[{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/"}],"drug":[{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/"}]}}